{"id":40652,"date":"2025-10-23T13:12:59","date_gmt":"2025-10-23T11:12:59","guid":{"rendered":"https:\/\/www.vismederiholding.com\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/"},"modified":"2025-10-23T13:15:14","modified_gmt":"2025-10-23T11:15:14","slug":"vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines","status":"publish","type":"post","link":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/","title":{"rendered":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals"},"content":{"rendered":"<div class=\"xdj266r x14z9mp xat24cr x1lziwak x1vvkbs x126k92a\">\n<div dir=\"auto\">\n<div class=\"x14z9mp xat24cr x1lziwak x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\">Siamo orgogliosi di aver contribuito all&#8217;importante risultato raggiunto da <strong>Clover Biopharmaceuticals<\/strong> nello sviluppo di <strong>vaccini combinati innovativi contro le malattie respiratorie.<\/strong><\/div>\n<div dir=\"auto\"><\/div>\n<div dir=\"auto\">VisMederi ha contribuito allo studio di <strong>fase I sui vaccini combinati RSV+hMPV\u00b1PIV3<\/strong> eseguendo analisi sierologiche e supportando la generazione di dati chiave che dimostrano il potenziale dei vaccini candidati di nuova generazione di Clover.<\/div>\n<\/div>\n<div class=\"x14z9mp xat24cr x1lziwak x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\">Questi risultati preliminari positivi rappresentano un passo significativo verso la risposta alle esigenze non soddisfatte nella prevenzione delle malattie respiratorie, compresa una protezione pi\u00f9 ampia che va oltre il solo<strong> RSV.<\/strong><\/div>\n<\/div>\n<div class=\"x14z9mp xat24cr x1lziwak x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\">Questa collaborazione riflette il nostro impegno costante verso l&#8217;<strong>eccellenza scientifica<\/strong> e la collaborazione con partner globali che condividono la nostra stessa visione: sviluppare strumenti innovativi per migliorare la salute pubblica in tutto il mondo.<\/div>\n<\/div>\n<div class=\"x14z9mp xat24cr x1lziwak x1vvkbs xtlvy1s x126k92a\">\n<div dir=\"auto\">Per saperne di pi\u00f9: <span class=\"html-span xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x1hl2dhg x16tdsg8 x1vvkbs\"><a class=\"x1i10hfl xjbqb8w x1ejq31n x18oe1m7 x1sy0etr xstzfhl x972fbf x10w94by x1qhh985 x14e42zd x9f619 x1ypdohk xt0psk2 x3ct3a4 xdj266r x14z9mp xat24cr x1lziwak xexx8yu xyri2b x18d9i69 x1c1uobl x16tdsg8 x1hl2dhg xggy1nq x1a2a7pz xkrqix3 x1sur9pj x1fey0fg x1s688f\" role=\"link\" href=\"https:\/\/www.prnewswire.com\/news-releases\/clover-announces-positive-phase-i-clinical-data-for-rsv-hmpv-piv3-combination-vaccines-and-for-rsv-re-vaccination-in-older-adults-302583277.html?fbclid=IwZXh0bgNhZW0CMTAAYnJpZBExaVp4bE56WFlWRHlvSzBJeAEeunyIkrY4lMg34gCbSi6Ow4PcbDQYDmpMZOsVFB5DPQTEy_gF8zOYKURdvPM_aem_4VsLgQjvZBs0rEs7u_ufIQ\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">https:\/\/www.prnewswire.com\/&#8230;\/clover-announces-positive&#8230;<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"x14z9mp xat24cr x1lziwak x1vvkbs xtlvy1s x126k92a\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Siamo orgogliosi di aver contribuito all&#8217;importante risultato raggiunto da Clover Biopharmaceuticals nello sviluppo di vaccini combinati innovativi contro le malattie respiratorie. VisMederi ha contribuito allo studio di fase I sui vaccini combinati RSV+hMPV\u00b1PIV3 eseguendo analisi sierologiche e supportando la generazione di dati chiave che dimostrano il potenziale dei vaccini candidati di nuova generazione di Clover. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":40650,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[109],"tags":[157,170,120,165,185,128,159,118,122,151,155],"dipi_cpt_category":[],"class_list":["post-40652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newseventi","tag-immunization-it","tag-international-study-it","tag-meningitis-vaccine-project-it","tag-research-it","tag-serological-testing-it","tag-siena-it","tag-vaccinations-it","tag-vaccines-it","tag-vismederi-it","tag-vismederi-group-it","tag-viusmederi-siena-it"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding\" \/>\n<meta property=\"og:description\" content=\"Siamo orgogliosi di aver contribuito all&#8217;importante risultato raggiunto da Clover Biopharmaceuticals nello sviluppo di vaccini combinati innovativi contro le malattie respiratorie. VisMederi ha contribuito allo studio di fase I sui vaccini combinati RSV+hMPV\u00b1PIV3 eseguendo analisi sierologiche e supportando la generazione di dati chiave che dimostrano il potenziale dei vaccini candidati di nuova generazione di Clover. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/\" \/>\n<meta property=\"og:site_name\" content=\"Vismederi Holding\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-23T11:12:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T11:15:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Elec23\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elec23\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/\"},\"author\":{\"name\":\"Elec23\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"headline\":\"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals\",\"datePublished\":\"2025-10-23T11:12:59+00:00\",\"dateModified\":\"2025-10-23T11:15:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/\"},\"wordCount\":151,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Untitled-design.png\",\"keywords\":[\"Immunization\",\"International Study\",\"Meningitis Vaccine Project\",\"research\",\"Serological Testing\",\"siena\",\"vaccinations\",\"vaccines\",\"VisMederi\",\"vismederi group\",\"ViusMederi Siena\"],\"articleSection\":[\"News&amp;eventi\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/\",\"name\":\"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Untitled-design.png\",\"datePublished\":\"2025-10-23T11:12:59+00:00\",\"dateModified\":\"2025-10-23T11:15:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Untitled-design.png\",\"contentUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Untitled-design.png\",\"width\":1080,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\",\"name\":\"Vismederi Holding\",\"description\":\"A group with expertise in the evaluation of vaccine immunogenicity\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\",\"name\":\"Elec23\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"caption\":\"Elec23\"},\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/author\\\/elec23\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/","og_locale":"it_IT","og_type":"article","og_title":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding","og_description":"Siamo orgogliosi di aver contribuito all&#8217;importante risultato raggiunto da Clover Biopharmaceuticals nello sviluppo di vaccini combinati innovativi contro le malattie respiratorie. VisMederi ha contribuito allo studio di fase I sui vaccini combinati RSV+hMPV\u00b1PIV3 eseguendo analisi sierologiche e supportando la generazione di dati chiave che dimostrano il potenziale dei vaccini candidati di nuova generazione di Clover. [&hellip;]","og_url":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/","og_site_name":"Vismederi Holding","article_published_time":"2025-10-23T11:12:59+00:00","article_modified_time":"2025-10-23T11:15:14+00:00","og_image":[{"width":1080,"height":1350,"url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png","type":"image\/png"}],"author":"Elec23","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Elec23","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#article","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/"},"author":{"name":"Elec23","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"headline":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals","datePublished":"2025-10-23T11:12:59+00:00","dateModified":"2025-10-23T11:15:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/"},"wordCount":151,"commentCount":0,"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png","keywords":["Immunization","International Study","Meningitis Vaccine Project","research","Serological Testing","siena","vaccinations","vaccines","VisMederi","vismederi group","ViusMederi Siena"],"articleSection":["News&amp;eventi"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/","url":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/","name":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals - Vismederi Holding","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#primaryimage"},"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png","datePublished":"2025-10-23T11:12:59+00:00","dateModified":"2025-10-23T11:15:14+00:00","author":{"@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"breadcrumb":{"@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#primaryimage","url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png","contentUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/10\/Untitled-design.png","width":1080,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/www.vismederiholding.com\/it\/vismederi-contributes-to-clover-biopharmaceuticals-advancement-in-innovative-respiratory-combination-vaccines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vismederiholding.com\/it\/"},{"@type":"ListItem","position":2,"name":"Promuovere l\u2019innovazione nei vaccini respiratori: il contributo di VisMederi allo studio di Fase I di Clover Biopharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.vismederiholding.com\/it\/#website","url":"https:\/\/www.vismederiholding.com\/it\/","name":"Vismederi Holding","description":"A group with expertise in the evaluation of vaccine immunogenicity","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vismederiholding.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c","name":"Elec23","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","caption":"Elec23"},"url":"https:\/\/www.vismederiholding.com\/it\/author\/elec23\/"}]}},"_links":{"self":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/comments?post=40652"}],"version-history":[{"count":1,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40652\/revisions"}],"predecessor-version":[{"id":40653,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40652\/revisions\/40653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media\/40650"}],"wp:attachment":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media?parent=40652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/categories?post=40652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/tags?post=40652"},{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/dipi_cpt_category?post=40652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}